WAC-a-mol

While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But they are likely to result in lower co-pays for patients, which could increase access.

On March 28, FDA approved two drugs that were firsts for their indications: Dupixent dupilumab from Regeneron Pharmaceuticals Inc. and Sanofi to treat moderate-to-severe atopic dermatitis in patients not adequately controlled with topical therapies; and Ocrevus ocrelizumab from Roche’s Genentech Inc. unit to treat primary progressive multiple sclerosis (PPMS). Ocrevus also was approved for relapsing-remitting MS (RRMS). ...